Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hansen

Showing results (1491-1500 of 1,581) with videos related to

Pageof 159
Sort By:
Shock (Augusta, Ga.)|December 11, 2012
Tranexamic acid and trauma: current status and knowledge gaps with recommended research prioritiesAnthony E Pusateri, Richard B Weiskopf, Vikhyat Bebarta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid TumorsAtish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Nature Communications|August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityS Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Eclinicalmedicine|October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtableChristina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
NPJ Precision Oncology|February 13, 2026
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumabEric Y Stutheit-Zhao, Yongqi Zhong, Collin A Melton, et al.
Cardiovascular Research|August 21, 2024
Smooth muscle-specific deletion of cellular communication network factor 2 causes severe aorta malformation and atherosclerosisJannik H Larsen, Julie S Hegelund, Matilde K Pedersen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 16, 2023
Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION NetworkKatherine Adams, Zachary A Weber, Duck-Hye Yang, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyMarc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Nature Communications|June 24, 2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficienciesJohn Hilton, Karen Gelmon, Philippe L Bedard, et al.
Journal for Immunotherapy of Cancer|March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Pageof 159

Showing results (1491-1500 of 1,581) with videos related to

Sort By:
Pageof 159
Shock (Augusta, Ga.)|December 11, 2012
Tranexamic acid and trauma: current status and knowledge gaps with recommended research prioritiesAnthony E Pusateri, Richard B Weiskopf, Vikhyat Bebarta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid TumorsAtish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Nature Communications|August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityS Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Eclinicalmedicine|October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtableChristina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
NPJ Precision Oncology|February 13, 2026
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumabEric Y Stutheit-Zhao, Yongqi Zhong, Collin A Melton, et al.
Cardiovascular Research|August 21, 2024
Smooth muscle-specific deletion of cellular communication network factor 2 causes severe aorta malformation and atherosclerosisJannik H Larsen, Julie S Hegelund, Matilde K Pedersen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 16, 2023
Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION NetworkKatherine Adams, Zachary A Weber, Duck-Hye Yang, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyMarc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Nature Communications|June 24, 2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficienciesJohn Hilton, Karen Gelmon, Philippe L Bedard, et al.
Journal for Immunotherapy of Cancer|March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Pageof 159